Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Despite the well-documented association between insulin resistance and cardiovascular disease, the key targets of insulin relevant to the development of cardiovascular disease are not known. Here, using non-biased profiling methods, we identify the enzyme flavin-containing monooxygenase 3 ( Fmo3 ) to be a target of insulin. FMO3 produces trimethylamine N-oxide (TMAO), which has recently been suggested to promote atherosclerosis in mice and humans. We show that FMO3 is suppressed by insulin in vitro , increased in obese/insulin resistant male mice and increased in obese/insulin-resistant humans. Knockdown of FMO3 in insulin-resistant mice suppresses FoxO1, a central node for metabolic control, and entirely prevents the development of hyperglycaemia, hyperlipidemia and atherosclerosis. Taken together, these data indicate that FMO3 is required for FoxO1 expression and the development of metabolic dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insights into the mechanisms through which the meta-organismal pathway responsible for TMAO production are associated with enhanced CVD risks have thus far focused on the involvement of TMAO and FMO3 in atherosclerotic plaque development, altered sterol and glucose metabolism, and changes in macrophage phenotype (Wang et al., 2011 ; Koeth et al., 2013; Miao et al., 2015 ; Shih et al., 2015; War”
From Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk (2016) · cites this paper as Miao et al., 2015
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Knockdown of FMO3 in LIRKO mice suppressed FoxO1 expression (and improved glucose tolerance) by upregulating sterol regulatory element binding protein 2 (SREBP2) (77).”
From Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease (2017) · cites this paper as [77]
In the citing paper
“suppression of the host enzyme, FMO3, through antisense oligonucleotide-based approach, results in reduction of both circulating TMAO levels and diet-enhanced atherosclerosis in animal models”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Miao et al., 2015
In the citing paper
“Taken together, these data suggest that FMO3, which is differentially regulated in male and female mice, is necessary but apparently not sufficient for the development of the diabetic phenotype.”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [76]
In the citing paper
“downregulation or knock-out of FMO3 leads to decreased levels of TMAO and it is athero-protective in these models, whereas increased expression of FMO3 leads to pro-atherogenic lipid profiles (e.g., higher VLDL and LDL) [75,76].”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [76]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
affy—analysis of Affymetrix GeneChip data at the probe level
Gautier, L., Cope, L., Bolstad, B. M., & Irizarry, R. A. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg405 · Cited by 5,218
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,378
Research works printed but not linked: 2
- Shih, D. M. et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res 56, 22–37 (2015) . · DOI · Paper page
- Roberts, L. D., Souza, A. L., Gerszten, R. E. & Clish, C. B. Curr. Protoc. Mol. Biol eds Frederick M. A.et al. Chapter 30, Unit 30 32 31-24 (2012) .
Cited by
Items 101–200 of 372
Emerging roles of flavin monooxygenase 3 in cholesterol metabolism and atherosclerosis
Schugar, R. C., & Brown, J. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000215 · Cited by 65
YAP suppresses gluconeogenic gene expression through PGC1α
Hu, Y., Shin, D., Pan, H., Lin, Z., Dreyfuss, J. M., Camargo, F. D., Miao, J., & Biddinger, S. B. (2017) · Hepatology · doi:10.1002/hep.29373 · Cited by 62
Self-citationElevated plasma trimethylamine-N-oxide levels are associated with diabetic retinopathy
Liu, W., Wang, C., Xia, Y., Xia, W. T., Liu, G., Ren, C., Gu, Y., Li, X., & Lu, P. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01610-9 · Cited by 71
Serban, M.-C., Sahebkar, A., Mikhailidis, D. P., Toth, P. P., Jones, S. R., Muntner, P., Blaha, M. J., Andrica, F., Martin, S. S., Borza, C., et al. (2016) · Scientific Reports · doi:10.1038/srep19188 · Cited by 64
FMO3 and its metabolite TMAO contribute to the formation of gallstones
Chen, Y., Weng, Z., Liu, Q., Shao, W., Guo, W., Chen, C., Jiao, L., Wang, Q., Lu, Q., Sun, H., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.06.016 · Cited by 66
Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?
Jiang, L., & Schnabl, B. (2020) · Physiology · doi:10.1152/physiol.00005.2020 · Cited by 77
Orman, M., Bodea, S., Funk, M. A., Campo, A. M.-D., Bollenbach, M., Drennan, C. L., & Balskus, E. P. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b04883 · Cited by 69
Li, S., Chen, S. X., Lu, X., Fang, A., Chen, Y., Huang, R.-Z., Lin, X., Huang, Z.-H., Ma, J.-F., Huang, B., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03581-7 · Cited by 65
“Furthermore, manipulation of gut microbiota or knockdown of FMO3 in insulin-resistant mice inhibited TMAO production, reduced PERK activation and suppressed FoxO1 in the liver, which may prevent the development of hyperglycemia [11, 51].”
BackgroundGanz, A. B., Cohen, V. V., Swersky, C. C., Stover, J. A., Vitiello, G. A., Lovesky, J., Chuang, J. C., Shields, K. S., Fomin, V. G., Lopez, Y. S., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020252 · Cited by 65
“FMO3 is activated by insulin, and knockout in insulin resistant mice prevents hyperglycemia, hyperlipidemia, and atherosclerosis [38].”
BackgroundThe Gut Microbial Endocrine Organ in Type 2 Diabetes
Massey, W. J., & Brown, J. M. (2020) · Endocrinology · doi:10.1210/endocr/bqaa235 · Cited by 66
Altered nutrient status reprograms host inflammation and metabolic health via gut microbiota
Golonka, R. M., Xiao, X., Abokor, A. A., Joe, B., & Vijay–Kumar, M. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108360 · Cited by 61
TMA/TMAO in Hypertension: Novel Horizons and Potential Therapies
Zhang, W., Wang, Y., Zhang, A., Ding, Y., Zhang, X., Jia, Q.-J., Zhu, Y., Li, Y., Lv, S., & Zhang, J. (2021) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-021-10115-x · Cited by 62
DiNicolantonio, J. J., McCarty, M., & OKeefe, J. (2019) · Open Heart · doi:10.1136/openhrt-2018-000890 · Cited by 57
“65 With respect to the impact of insulin, genetically modified mice in which hepatic expression of the insulin receptor has been selectively ablated (Liver-specific insulin receptor knockout mice) have greatly enhanced hepatic expression of FMO3.(64) These mice develop marked hypercholesterolaemia and are exceptionall…”
BackgroundInfluentialA Gut Feeling about Thrombosis
Tilg, H. (2016) · New England Journal of Medicine · doi:10.1056/nejmcibr1604458 · Cited by 60
Trimethylamine N‐oxide as a risk marker for ischemic stroke in patients with atrial fibrillation
Liang, Z., Dong, Z., Guo, M., Shen, Z., Yin, D., Hu, S., & Hai, X. (2019) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22246 · Cited by 57
The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease
Hage, R. E., Al-Arawe, N., & Hinterseher, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032399 · Cited by 62
Mechanisms linking gut microbial metabolites to insulin resistance
Jang, H. R., & Lee, H. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i6.730 · Cited by 56
Yang, J. J., Shu, X., Herrington, D. M., Moore, S. C., Meyer, K. A., Ose, J., Menni, C., Palmer, N. D., Eliassen, A. H., Harada, S., et al. (2020) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa430 · Cited by 56
Kuka, J., Ozola, M., Makrecka‐Kuka, M., Liepiņš, J., Grīnberga, S., Sevostjanovs, E., Vilks, K., Liepinsh, E., & Dambrova, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-71470-4 · Cited by 56
Wu, G., Zhang, W., & Li, H. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112057 · Cited by 54
Steuer, C., Schüetz, P., Bernasconi, L., & Huber, A. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2015.12.002 · Cited by 53
Dong, Z., Liang, Z., Guo, M., Hu, S., Shen, Z., & Hai, X. (2018) · Disease Markers · doi:10.1155/2018/1578320 · Cited by 57
Coras, R., Kavanaugh, A., Boyd, T., Huynh, D., Lagerborg, K. A., Xu, Y., Rosenthal, S. B., Jain, M., & Gumá, M. (2019) · PubMed · Cited by 73
Lv, Q., Li, Z., Sui, A., Yang, X., Han, Y., & Yao, R. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.977187 · Cited by 59
Trimethylamine N-oxide: a meta-organismal axis linking the gut and fibrosis
Jang, J. W., Capaldi, E., Smith, T. L., Verma, P., Varga, J., & Ho, K. J. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00895-8 · Cited by 54
“(Zhang et al. 2017; Miao et al. 2015) However, suppression of FMO3 has likely little clinical potential as inhibition of this enzyme has been shown to cause hepatic inflammation.”
BackgroundPCOS without hyperandrogenism is associated with higher plasma Trimethylamine N-oxide levels
Huang, J., Liu, L., Chen, C., & Gao, Y. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0486-9 · Cited by 49
“Another proposed mechanism between IR and TMAO levels is that IR and the corresponding increased plasma levels of insulin upregulate the activity of flavincontaining monooxygenase 3 (FMO-3) and hence increase TMAO levels [35], indicating that high TMAO levels might contribute to the onset of PCOS.”
BackgroundTargeting the human microbiome and its metabolite TMAO in cardiovascular prevention and therapy
Dannenberg, L., Zikeli, D., Benkhoff, M., Ahlbrecht, S., Kelm, M., Levkau, B., & Polzin, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107584 · Cited by 55
Microbiota in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Guan, D., Wang, Z., Li, X., Dong, S., Huang, J., & Zhou, W. (2023) · MedComm · doi:10.1002/mco2.417 · Cited by 50
“184,185 In other experiments, it was discovered that bile acids hindered the ability of DU-145 migratory prostate cancer cells to adhere, migrate and invade.”
BackgroundPetriello, M. C., Hoffman, J. B., Sunkara, M., Wahlang, B., Perkins, J. T., Morris, A. J., & Hennig, B. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.03.016 · Cited by 49
“Also, downregulation of FMO3 has been shown to prevent the development of hyperlipidemia, atherosclerosis, and hyperglycaemia in a mouse model of insulin resistance [33].”
BackgroundMethodArgyridou, S., Davies, M. J., Biddle, G. J. H., Bernieh, D., Suzuki, T., Dawkins, N. P., Rowlands, A. V., Khunti, K., Yates, T. E., & Smith, A. C. (2021) · Journal of Nutrition · doi:10.1093/jn/nxab046 · Cited by 52
Trimethylamine/Trimethylamine-N-Oxide as a Key Between Diet and Cardiovascular Diseases
He, S., Jiang, H., Zhuo, C., & Jiang, W. (2021) · Cardiovascular Toxicology · doi:10.1007/s12012-021-09656-z · Cited by 49
“[24, 68] found that TMAO activates protein kinase R-like endoplasmic reticulum kinase (PERK) and promotes metabolic dysfunction in mouse hepatocytes, which explained the phenomenon that mice without FMO3 showed improved glucose tolerance .”
BackgroundVallance, H. D., Koochin, A., Branov, J., Rosen-Heath, A., Bosdet, T., Wang, Z., Hazen, S. L., & Horvath, G. A. (2018) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2018.04.005 · Cited by 49
Schmedes, M. S., Aadland, E. K., Sundekilde, U. K., Jacques, H., Lavigne, C., Graff, I. E., Eng, Ø., Holthe, A., Mellgren, G., Young, J. F., et al. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500785 · Cited by 48
“Recently, it was shown that a high hepatic FMO3 activity, rather than the TMAO concentration itself, was the underlying mechanism to the development of metabolic dysfunctions [42].”
BackgroundGut microbial metabolite TMAO portends prognosis in acute ischemic stroke
Zhang, J., Wang, L., Cai, J., Lei, A., Liu, C., Lin, R., Li, J., & Fu, Y. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577526 · Cited by 49
TMAO and diabetes: from the gut feeling to the heart of the problem
Jaworska, K., Kuś, M., & Ufnal, M. (2025) · Nutrition and Diabetes · doi:10.1038/s41387-025-00377-8 · Cited by 48
“Speci fi cally, they demonstrated that one of insulin ’ s most signi fi cant effects on the mouse liver in vivo is to suppress FMO3 and TMAO, a function that is impaired in insulin-resistant states [75].”
miRNA and cholesterol homeostasis
Jeon, T.-I., & Osborne, T. F. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.01.005 · Cited by 47
“miR-182 targets FBXW7 and miR-96 targets INSIG2 thereby creating a positive-feedback loop to regulate SREBP activity for cholesterol homeostasis [20,21] (Fig.”
BackgroundSchmedes, M. S., Brejnrod, A., Aadland, E. K., Kiilerich, P., Kristiansen, K., Jacques, H., Lavigne, C., Graff, I. E., Eng, Ø., Holthe, A., et al. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700976 · Cited by 46
“Recently, it was shown in mice that high FMO3 activity, rather than the TMAO concentration itself was the underlying mechanism to the development of metabolic dysfunctions [48].”
BackgroundUse of dietary phytochemicals for inhibition of trimethylamine N-oxide formation
Iglesias‐Carres, L., Hughes, M. D., Steele, C. N., Ponder, M. A., Davy, K. P., & Neilson, A. P. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108600 · Cited by 45
Wei, D., Li, Y., Che, M., Li, C., Wu, Q., & Sun, C. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04412-0 · Cited by 43
“In liver, FMO3 has been identified to be positively correlated with insulin resistance, cardiovascular diseases, and other metabolic disorders [65].”
BackgroundThe gut microbiota‐astrocyte axis: Implications for type 2 diabetic cognitive dysfunction
Li, Z.-H., Jiang, Y., Long, C., Peng, Q., & Yue, R. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14077 · Cited by 43
Krueger, E. S., Lloyd, T. S., & Tessem, J. S. (2021) · Nutrients · doi:10.3390/nu13082873 · Cited by 42
“Non-biased metabolomic studies identified TMAO and FMO3 as targets of insulin signaling [48].”
BackgroundInfluentialYang, S., Li, D., Yu, Z., Li, Y., & Wu, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.709629 · Cited by 40
“Its silencing or overexpression directly affects systemic TMAO levels and changes cholesterol and lipid metabolism, as well as platelet reactivity and thrombosis in different mouse strains (Bennett et al., 2013; Miao et al., 2015; Schugar and Brown, 2015; Warrier et al., 2015; Zhu et al., 2018b).”
BackgroundRoy, S. S., yuzefpolskaya, M., Nandakumar, R., Colombo, P. C., & Demmer, R. T. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227482 · Cited by 40
“Others have demonstrated that knockdown of flavin containing monooxygenase 3 (FMO3)–which produces TMAO–in insulin resistant mice blocks the development of hyperglycemia[7].”
BackgroundMicrobiota and metabolites in rheumatic diseases
Tong, Y., Marion, T. N., Schett, G. A., Luo, Y., & Liu, Y. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102530 · Cited by 43
Shi, W., Huang, Y., Zhou, Y., Zhu, L., & Yu, B. (2021) · Bioscience Reports · doi:10.1042/bsr20204250 · Cited by 42
Baeyer–Villiger Monooxygenase FMO5 as Entry Point in Drug Metabolism
Fiorentini, F., Romero, E., Fraaije, M. W., Faber, K., Hall, M., & Mattevi, A. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00470 · Cited by 38
He, M., Tan, C. P., Xu, Y., & Liu, Y. (2020) · Food Research International · doi:10.1016/j.foodres.2020.109812 · Cited by 37
Chleilat, F., Schick, A., Deleemans, J. M., Ma, K., Alukic, E., Wong, J., Tuplin, E. W. N., Nettleton, J. E., & Reimer, R. A. (2021) · The FASEB Journal · doi:10.1096/fj.202100198rr · Cited by 42
Kim, S.-J., Bale, S., Verma, P., Wan, Q., Ma, F., Gudjonsson, J. E., Hazen, S. L., Harms, P. W., Tsou, P., Khanna, D., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104669 · Cited by 37
“Hepatic and extrahepatic expression of FMO3 is variable and has been shown to be altered in a variety of conditions, including insulin resistance (Miao et al., 2015).”
BackgroundThe microbiome and its pharmacological targets: therapeutic avenues in cardiometabolic diseases
Neves, A. L., Chilloux, J., Sarafian, M. H., Rahim, M. B. A., Boulangé, C. L., & Dumas, M.-E. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.013 · Cited by 36
Diet and Gut Microbial Function in Metabolic and Cardiovascular Disease Risk
Meyer, K. A., & Bennett, B. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0791-x · Cited by 37
Mihuţa, M. S., Paul, C., Borlea, A., Roi, C. M., Pescari, D., Velea-Barta, O.-A., Mozos, I. M., & Stoian, D. L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1253584 · Cited by 35
“Childhood obesity has developed into a public health problem that necessitates ongoing attention and effort to slow down because of all the variables contributing to its worsening over time (3 – 7).”
The Gut Microbiome and Xenobiotics: Identifying Knowledge Gaps
Sutherland, V. L., McQueen, C. A., Mendrick, D. L., Gulezian, D., Cerniglia, C. E., Foley, S. L., Forry, S., Khare, S., Liang, X., Manautou, J. E., et al. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa060 · Cited by 33
“TMAO blood levels are of interest as a biomarker for CVD, insulin resistance, and type 2 diabetes (Miao, 2015).”
BackgroundWei, H., Zhao, M., Huang, M., Li, C., Gao, J., Yu, T., Zhang, Q., Shen, X., Liang, J., Ni, L., et al. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0857-2 · Cited by 35
Yu, H., Chai, X., Geng, W., Zhang, L., Ding, F., Guo, D., & Wang, Y. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113488 · Cited by 33
FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1
Ke, C., Xiao, C., Li, J., Wu, X., Zhang, Y., Chen, Y., Sheng, S., Fu, Z., Wang, L., Ni, C., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000643 · Cited by 35
“[23] For FMO2, a study showed that FMO2 is significantly downregulated in the livers of obese mice.”
Li, D., Chen, R., Xu, X., Hou, Y., Li, Z., Huang, C., Zhang, G., Wang, B., Li, B., & Chu, X. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156138 · Cited by 33
Massmig, M., Reijerse, E. J., Krausze, J., Laurich, C., Lubitz, W., Jahn, D., & Moser, J. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014266 · Cited by 33
Krueger, E. S., Beales, J. L., Russon, K. B., Elison, W. S., Davis, J., Hansen, J. M., Neilson, A. P., Hansen, J. M., & Tessem, J. S. (2021) · Biomolecules · doi:10.3390/biom11121892 · Cited by 33
Wang, R., Bao, W., Pal, M., Liu, Y., Yazdanbakhsh, K., & Zhong, H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003539 · Cited by 35
Inactivation mechanism of N61S mutant of human FMO3 towards trimethylamine
Gao, C., Catucci, G., Castrignanò, S., Gilardi, G., & Sadeghi, S. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-15224-9 · Cited by 33
microRNA-146a-5p association with the cardiometabolic disease risk factor TMAO
Coffey, A. R., Kanke, M., Smallwood, T., Albright, J., Pitman, W. A., Gharaibeh, R. Z., Hua, K., Gertz, E., Biddinger, S. B., Temel, R. E., et al. (2019) · Physiological Genomics · doi:10.1152/physiolgenomics.00079.2018 · Cited by 32
“LIRKO mice are known to have elevated TMAO levels in circulation compared with their floxed controls even when fed a chow diet (29), and our measurements of circulating TMAO corroborated this finding (Fig.”
BackgroundResultSelf-citationInfluence of the gut microbiome on inflammatory and immune response after stroke
Huang, Q., & Xia, J. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05603-6 · Cited by 34
Metabolic-Associated Fatty Liver Disease and the Gut Microbiota
Barber, T. M., Hanson, P., & Weickert, M. O. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.01.004 · Cited by 36
Schugar, R. C., Willard, B. B., Wang, Z., & Brown, J. M. (2017) · Adipocyte · doi:10.1080/21623945.2017.1398295 · Cited by 31
The gut-heart axis: unveiling the roles of gut microbiota in cardiovascular diseases
Zhang, Y., Wu, H., Jin, M., Feng, G., & Wang, S. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1572948 · Cited by 37
“Research on the antisense oligonucleotide-based regulation of FMO3 in animal models revealed a decrease in TMAO serum levels concurrent with a reduction in diet-enhanced atherosclerosis (223).”
Li, D., Kirsop, J., & Tang, W. H. W. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0634-1 · Cited by 29
Evidence of adequacy of postpartum care for immigrant women.
Katz, D., & Gagnon, A. J. (2002) · PubMed · Cited by 32
Zhao, Y., Yang, N., Gao, J., Li, H., Cai, W., Zhang, X., Ma, Y., Niu, X., Yang, G., Zhou, X., et al. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700299 · Cited by 29
Bollenbach, M., Ortega, M. A., Orman, M., Drennan, C. L., & Balskus, E. P. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00005 · Cited by 30
Understanding connections and roles of gut microbiome in cardiovascular diseases
Rajendiran, E., Ramadass, B., & Ramprasath, V. R. (2020) · Canadian Journal of Microbiology · doi:10.1139/cjm-2020-0043 · Cited by 31
The microbial-mammalian metabolic axis: a critical symbiotic relationship
Chilloux, J., Neves, A. L., Boulangé, C. L., & Dumas, M. (2016) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000284 · Cited by 33
Circulating MiRNA biomarkers serve as a fingerprint for diabetic atherosclerosis.
Zhang, J., Gong, Y., Li, C., Qi, Q., Zhang, Q.-M., & Yu, D. (2016) · Europe PMC (PubMed Central) · Cited by 28
The roles of different microRNAs in the regulation of cholesterol in viral hepatitis
Meng, X., Eslami, Y., Derafsh, E., Saihood, A. S., Emtiazi, N., Yasamineh, S., Gholizadeh, O., & Pecho, R. D. C. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01250-w · Cited by 29
“MiR-182 regulates SREBP activity for cholesterol homeostasis by targeting FBXW7, while miR-96 regulates SREBP activity by targeting INSIG2 [21, 66, 67].”
BackgroundLiu, J., Li, F., Yang, L., Luo, S., & Deng, Y. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1554189 · Cited by 39
Trimethylamine N-oxide—a marker for atherosclerotic vascular disease
Xie, G., An, Y., Lin, P., Wang, Y., & Guo, L. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203085 · Cited by 28
“However, this effect was smaller than that seen in the mouse model, possibly because diabetic patients were treated with insulin and/or other drugs to increase insulin sensitivity [61].”
BackgroundTime‐limited diets and the gut microbiota in cardiometabolic disease
Ratiner, K., Shapiro, H., Goldenberg, K., & Elinav, E. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13288 · Cited by 27
“It has been previously suggested that maintaining low levels of TMAO may be particularly helpful in preventing T2D-associated cardiomyopathy.(177) Recently, elevated TMAO levels were found in db/db mice during both daytime and nighttime, which was associated with loss of diurnal oscillations of various gut bacteria.”
Backgroundwild-type choline TMA lyase in complex with betaine aldehyde
Funk, M. A., & Drennan, C. L. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6nd3/pdb · Cited by 27
Gut Microbe-Generated Metabolite Trimethylamine-N-Oxide and Ischemic Stroke
Li, Z., He, X., Fang, Q., & Yin, X. (2024) · Biomolecules · doi:10.3390/biom14111463 · Cited by 31
Bica, I.-C., Pietroșel, V.-A., Salmen, T., Diaconu, C.-T., Fierbinteanu-Braticevici, C. G., Stoica, R. A., Suceveanu, A., & Stoian, A. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087184 · Cited by 27
Guo, D., Shen, Y., Li, W., Li, Q., Miao, Y., & Zhong, Y. (2020) · Aging · doi:10.18632/aging.102666 · Cited by 26
Circulating Gut Microbe-Derived Metabolites Are Associated with Hepatocellular Carcinoma
Banerjee, R., Wehrle, C. J., Wang, Z., Wilcox, J. D., Uppin, V., Varadharajan, V., Mrdjen, M., Hershberger, C. E., Reizes, O., Yu, J. S., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12091946 · Cited by 25
Zeng, Q., Zhao, M., Wang, F., Li, Y., Li, H., Zheng, J., Chen, X., Zhao, X., Liang, J., Gao, X., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.906310 · Cited by 27
Gao, H. Y., Song, R., Jiang, H., Zhang, W., & Han, S. (2021) · Nutrition · doi:10.1016/j.nut.2021.111558 · Cited by 27
Role of gut microbe-derived metabolites in cardiometabolic diseases: Systems based approach
Cao, Y., Aquino-Martínez, R., Hutchison, E. R., Allayee, H., Lusis, A. J., & Rey, F. E. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101557 · Cited by 29
“Interestingly, insulin resistance increases FMO3 activity in the liver of both human and mice, which leads to increased TMAO levels and metabolic dysfunction over time [58].”
BackgroundMetabonomic profiling of chronic intermittent hypoxia in a mouse model
Conotte, S., Tassin, A., Conotte, R., Colet, J., Boudjeltia, K. Z., & Legrand, A. (2018) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2018.02.015 · Cited by 26
Chilloux, J., Brial, F., Everard, A., Smyth, D. R., Andrikopoulos, P., Zhang, L., Plovier, H., Myridakis, A., Hoyles, L., Moreno‐Navarrete, J. M., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01413-8 · Cited by 26
“Consistent with our observations, https://doi.org/10.1038/s42255-025-01413-8 Fmo3 deletion prevented hyperglycaemia, hyperlipidemia and atherosclerosis in mice and is considered a target for dysmetabolism 23 .”
InfluentialWang, J., Long, C., Zhang, H., Zhang, Y., Wang, H., Yue, H., Wang, X., Wu, S., & Qi, G. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.16472 · Cited by 28
“Knockdown of FMO3 decreases hepatic and plasma lipids levels in LDL receptor knockout mice [8], decreases VLDL- and LDL-associated cholesterol in liver insulin receptor-knockout mice [42], and limits the production of hepatic oxysterols and cholesteryl esters in cholesterol-fed mice [9].”
BackgroundFeng, X., Deng, M., Zhang, L., & Pan, Q. (2023) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2023-0116 · Cited by 23
“[104,105] Research has shown that TMA and TMAO peak levels occur approximately 4 hours after a single feeding of a high-fat diet in fasted mice, indicating that TMA and TMAO are produced after meals and exhibit hormonal oscillations related to TMA source nutrient intake.”
BackgroundFecal Microbiota Transplantation: A Prospective Treatment for Type 2 Diabetes Mellitus
Zhou, X., Chen, R., Cai, Y., & Chen, Q. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s447784 · Cited by 25
“68,69 TMAO can also promote the release of pro-inflammatory factors such as IL-6 and TNF-α in vivo by activating NF-κB, increasing the possibility of vascular r-associated inflammation.”
BackgroundSun, X., Haas, M. E., Miao, J., Mehta, A. J., Graham, M. J., Crooke, R. M., de Barros, J.-P. P., Wang, J., Aikawa, M., Masson, D., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.668269 · Cited by 23
“3% SDS, 10 mM NaF, 10 mM Na3VO4, 10 mM sodium -glycerophosphate, and protease inhibitors (Roche Applied Science), centrifuging at 13,000 g for 10 min at 4 °C, and collecting the supernatant as described previously (24).”
MethodSelf-citationThe Intriguing Link between the Intestinal Microbiota and Cardiovascular Disease
Danese, E., Mattiuzzi, C., Favaloro, E. J., & Lippi, G. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1597903 · Cited by 27
The Role of the Microbiota in the Diabetic Peripheral Artery Disease
Biscetti, F., Nardella, E., Cecchini, A. L., Landolfi, R., & Flex, A. (2019) · Mediators of Inflammation · doi:10.1155/2019/4128682 · Cited by 26
“Several data suggest that infections resulting from periodontal or gut microbes have a direct influence on our endocrine system, on PVAT, and on pituitary-suprarenal action, with a possible derived imbalance of the autonomic sympathetic nervous system and metabolism homeostasis that could induce hypertension, insulin…”
InfluentialGanapathy, T. P., Yuan, J.-T., Ho, M. Y.-M., Wu, K. K.-L., Hoque, M. M., Wang, B., Li, X., Wang, K., Wabitsch, M., Feng, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63905-1 · Cited by 26
“Early human and animal studies showed the important role of this microbiota-host axis in cardiometabolic health 22,23,25 .”
Metabolic-Associated Fatty Liver Disease and Insulin Resistance: A Review of Complex Interlinks
Barber, T. M., Kabisch, S., Pfeiffer, A. F. H., & Weickert, M. O. (2023) · Metabolites · doi:10.3390/metabo13060757 · Cited by 24
Coronary heart disease and intestinal microbiota
Liu, L., He, X., & Feng, Y. (2019) · Coronary Artery Disease · doi:10.1097/mca.0000000000000758 · Cited by 25
Wang, M., Li, L., Chen, Y., Lian, G., Wang, J., Zhang, J., Shan, K., Shang, L., Tian, F., & Jing, C. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04974-7 · Cited by 23
“and its biosynthetic pathways may contribute to the regulation of glucose metabolism and insulin sensitivity [85].”
BackgroundBabu, A. K. S., Petersen, C., Iglesias‐Carres, L., Paz, H. A., Wankhade, U. D., Neilson, A. P., & Babu, P. V. A. (2023) · BioFactors · doi:10.1002/biof.2014 · Cited by 22
Haas, M., Brandl, B., Neuhaus, K., Wudy, S. I., Kleigrewe, K., Hauner, H., & Skurk, T. (2025) · European Journal of Clinical Nutrition · doi:10.1038/s41430-025-01636-8 · Cited by 24
“…to elevated TMAO levels and, consequently, an increased risk of CVD. Evidence suggests that higher FMO3 expression correlates with increased plasma TMAO concentrations [31] and mechanistic studies in mice indicate that FMO3 suppression reduces TMAO levels and atherosclerosis progression [32].”
Massey, W. J., Osborn, L. J., Banerjee, R., Horak, A. J., Fung, K. K., Orabi, D., Chan, E. R., Sangwan, N., Wang, Z., & Brown, J. M. (2022) · Metabolites · doi:10.3390/metabo12040364 · Cited by 22
“Given that human epidemiological and rodent studies have demonstrated that both TCDD exposure [1–4] and alterations in the FMO3–TMAO pathway [20,21,26] are associated with glucose intolerance, we subjected our mice to an intraperitoneal glucose tolerance test (GTT) after 4 weeks of TCDD exposure.”
BackgroundMethod
Metadata
- Authors
- Miao, J., Ling, A. V., Manthena, P. V., Gearing, M. E., Graham, M. J., Crooke, R. M., Croce, K. J., Esquejo, R. M., Clish, C. B., Morbid Obesity Study Group, Torrecilla, E., Vázquez, G. F., Rubio, M. A., Cabrerizo, L., Barabash, A., Pernaute, A. S., Torres, A. J., Vicent, D., & Biddinger, S. B.
- Affiliations
- Boston Children's Hospital (US)
- Ionis Pharmaceuticals (United States) (US)
- Brigham and Women's Hospital (US)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Broad Institute (US)
- Carlos III Hospital (ES)
- Hospital Clínico San Carlos (ES)
- Universidad Complutense de Madrid (ES)
- Corresponding author
- Biddinger, Sudha B.
- ORCID
- Venue
- Nature Communications
- Published
- 2015-04-07
- Volume
- 6
- Issue
- 1
- Pages
- 6498-6498
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4391288
- OpenAlex
- W2094278898
- Cited by
- 368
- References
- 58
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 26 · 2023: 35 · 2022: 41 · 2021: 40 · 2020: 44 · 2019: 30 · 2018: 33 · 2017: 29 · 2016: 35 · 2015: 9
- FWCI
- 30.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- American Heart Association
- Brigham and Women's Hospital
- Wake Forest University
- Broad Institute
- Institut National de la Santé et de la Recherche Médicale
- Sociedad de Endocrinología, Nutrición y Diabetes de la Comunidad de Madrid
- National Heart, Lung, and Blood Institute (R01HL048044, HL48044, HL109650, R01HL109650)
- National Institute of Diabetes and Digestive and Kidney Diseases (L40 DK065607, K99DK100539, DK-100539, R00DK100539)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- FMO3, insulin resistance, diabetes-associated atherosclerosis, trimethylamine N-oxide, FOXO1, obesity, hyperglycemia, hyperlipidemia, metabolic dysfunction, insulin signaling
- MeSH terms
- Forkhead Box Protein O1, Animals, Diabetes Mellitus, Type 2, Humans, Hyperglycemia, Hyperlipidemias, Hypoglycemic Agents, Insulin, Insulin Resistance, Cholesterol, HDL, Cholesterol, LDL, Liver, Male, Obesity, Oxygenases, RNA, Messenger, Triglycerides, Blotting, Western, Rats, Sprague-Dawley, Gene Expression Profiling, Hepatocytes, Atherosclerosis, Mice, Rats, Forkhead Transcription Factors, Gene Knockdown Techniques, Real-Time Polymerase Chain Reaction, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.